全球避孕设备市场 - 2025 至 2033 年

2024 年全球避孕设备市场规模达到 109.8 亿美元，预计到 2033 年将达到 193.7 亿美元，2025-2033 年预测期间的复合年增长率为 6.6%。

避孕装置是一种物理产品，透过阻止精子到达卵子或改变身体的荷尔蒙或物理环境来降低怀孕的可能性，从而防止怀孕。这些设备形式多样，男女均可使用。它们是最常见的避孕方法之一，与药丸或註射等荷尔蒙避孕方法并列。避孕设备为计划生育、生殖健康和人口控制提供了重要的解决方案。

在人口、社会、经济和医疗保健等多种因素的推动下，全球对避孕设备的需求一直在稳步增长。这种不断增长的需求主要受到人们对更好的计划生育、更有效的生殖控制、增强的性健康意识和新产品推出的渴望的影响。例如，2024 年 9 月，ConTIPI Medical 与 EVERSANA 合作，支援 ProVate 设备在美国商业发布。

市场动态：

驱动因素与约束因素

意识的提高和政府的倡议

不断增强的认知度和政府倡议极大地推动了避孕设备市场的成长，预计将在预测期内推动市场的发展。世界各国政府都将计划生育作为公共卫生的重要方面，并认识到计划生育对经济发展、医疗保健成本和性别平等有直接影响。许多国家已经启动国家计划生育项目，使广大民众更容易取得和负担得起避孕设备。

例如，印度的国家计划生育计划一直是该国避孕药具分发工作的基石。印度的目标是降低人口成长率，透过政府补贴和宣传活动，数百万人已经了解了现代避孕方法。 2020 年，印度使用子宫内避孕器和埋植剂等长效可逆避孕药 (LARC) 的人数增加。

无论是政府或非政府组织发起的宣传活动都为广大民众，特别是医疗资源匮乏的农村地区民众，提供了有关避孕方法的重要资讯。这些措施强调了避孕设备的好处，并提供准确的资讯以打击有关避孕的迷思和错误讯息。透过教育大众，特别是年轻人和妇女，政府和组织正在消除使用避孕药具的障碍，从而增加需求。

例如，在美国等国家，计划生育等组织开展教育项目，以提高人们对避孕方法的认识。这些项目旨在向人们提供有关生殖健康选择的信息，从而增加避孕方法的采用。 2021年，美国有超过240万人使用了计划生育协会提供的避孕服务，这显示了宣传计画的有效性。

副作用和健康问题

虽然避孕设备在预防怀孕和控制生殖方面具有显着的优势，但副作用和健康问题仍然是阻碍市场成长的关键因素。这些担忧常常导致人们在使用某些方法时犹豫不决，甚至可能导致在首次使用后停止使用，从而限制了它们的整体采用和市场扩张。

许多流行的避孕装置，特别是子宫内避孕器 (IUD)、植入物和阴道环等荷尔蒙避孕装置，都会向体内释放荷尔蒙。虽然这些方法在预防怀孕方面非常有效，但它们往往会带来一系列副作用，阻碍使用者继续使用。然而，插入时存在感染和子宫穿孔的风险，特别是在不是在无菌环境中或由经过培训的医疗专业人员进行的情况下。

有些人担心荷尔蒙避孕方法对健康的长期影响，包括生育问题或增加癌症风险。人们担心使用植入物或子宫内避孕器等荷尔蒙装置可能会降低生育能力或延迟停止使用后恢復正常生育能力。然而，这些担忧往往基于错误讯息或过时的研究。

目录

第一章：市场介绍和范围

• 报告目标
• 报告范围和定义
• 报告范围

第 2 章：高阶主管见解与关键要点

• 市场亮点和战略要点
• 主要趋势和未来预测
• 按产品类型分类的片段
• 技术片段
• 按性别分类的片段
• 按配销通路分类的片段
• 按地区分类的片段

第 3 章：动态

• 影响因素
  • 驱动程式
    • 提高意识和政府倡议
    • 避孕装置的不断进步
  • 限制
    • 副作用和健康问题
    • 避孕设备成本高昂
  • 机会
    • 政府倡议
  • 影响分析

第四章：战略洞察与产业展望

• 市场领导者和先驱者
  • 新兴先锋和杰出参与者
  • 拥有最大销售品牌的成熟领导者
  • 拥有成熟产品的市场领导者
• CXO 观点
• 最新进展与突破
• 案例研究/正在进行的研究
• 监管和报销情况
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲
• 波特五力分析
• 供应链分析
• 专利分析
• SWOT 分析
• 未满足的需求和差距
• 市场进入和扩张的推荐策略
• 情境分析：最佳情况、基本情况和最坏情况预测
• 定价分析和价格动态
• 关键意见领袖

第 5 章：避孕设备市场（依产品类型）

• 保险套
• 隔膜和子宫颈帽
• 海绵
• 阴道环
• 子宫内避孕器 (IUD)
• 皮下植入

第 6 章：避孕设备市场（依技术）

• 荷尔蒙避孕药
• 工具避孕

第 7 章：避孕设备市场（依性别）

• 男性
• 女性

第 8 章：避孕设备市场（依配销通路）

• 医院药房
• 零售药局
• 线上通路
• 其他的

第 9 章：避孕设备市场，按区域市场分析与成长机会

• 北美洲
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 南美洲
  • 巴西
  • 阿根廷
  • 南美洲其他地区
• 亚太
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 中东和非洲

第 10 章：竞争格局与市场定位

• 竞争概况和主要市场参与者
• 市占率分析与定位矩阵
• 策略伙伴关係、併购
• 产品组合和创新的关键发展
• 公司基准化分析

第 11 章：公司简介

• CooperSurgical, Inc.
• 公司概况
• 产品组合和描述
• 财务概览
• 主要进展
• SWOT 分析
• Pregna International Limited
• Reckitt Benckiser group
• Veru Inc.
• Bayer AG
• Abbvie Inc.
• EUROGINE, SL
• Mona Lisa NV
• Prosan International BV
• OCON Medical Ltd.

第 12 章：假设与研究方法

• 资料收集方法
• 数据三角测量
• 预测技术
• 数据验证和确认

第 13 章：附录

The global contraceptive devices market reached US$ 10.98 billion in 2024 and is expected to reach US$ 19.37 billion by 2033, growing at a CAGR of 6.6% during the forecast period of 2025-2033.

Contraceptive devices are physical products designed to prevent pregnancy by either obstructing sperm from reaching an egg or altering the body's hormonal or physical environment to make pregnancy less likely. These devices come in various forms and can be used by both men and women. They are one of the most common methods of birth control, alongside hormonal methods like pills or injections. Contraceptive devices provide a critical solution in family planning, reproductive health, and population control.

The demand for contraceptive devices has been steadily increasing worldwide, driven by a combination of demographic, social, economic, and healthcare-related factors. This growing demand is primarily influenced by the desire for better family planning, more effective control over reproduction, increasing awareness of sexual health, and novel product launches. For instance, in September 2024, ConTIPI Medical partnered with EVERSANA to support the US commercial launch of the ProVate device.

Market Dynamics: Drivers & Restraints

Rising Awareness and Government Initiatives

The rising awareness and government initiatives are significantly driving the growth of the contraceptive devices market and are expected to drive the market over the forecast period. Governments worldwide are prioritizing family planning as a key aspect of public health, recognizing that it has a direct impact on economic development, healthcare costs, and gender equality. Many countries have launched national family planning programs that make contraceptive devices more accessible and affordable to a broad population.

For instance, the National Family Planning Program in India has been a cornerstone of the country's contraceptive distribution efforts. India aims to reduce its population growth rate, and through government subsidies and awareness campaigns, millions of people have been introduced to modern contraceptive methods. In 2020, India saw an increase in the use of long-acting reversible contraceptives (LARCs) such as IUDs and implants.

Awareness campaigns, whether spearheaded by governments or NGOs, have brought crucial information about contraceptive methods to a wide range of people, particularly in underserved and rural areas. These initiatives emphasize the benefits of contraceptive devices and provide accurate information to combat myths and misinformation about contraception. By educating the public, particularly young people and women, governments and organizations are removing barriers to contraceptive use, leading to higher demand.

For instance, in countries like the United States, organizations like Planned Parenthood run education programs to raise awareness about contraceptive methods. These programs aim to equip individuals with information on their reproductive health options, thus increasing the adoption of contraceptive methods. In 2021, over 2.4 million people in the U.S. used contraceptive services provided by Planned Parenthood, illustrating the effectiveness of awareness programs.

Side Effects and Health Concerns

While contraceptive devices offer significant benefits in terms of preventing pregnancy and controlling reproduction, side effects and health concerns remain key factors that can hamper market growth. These concerns often lead to hesitancy in using certain methods and can even result in discontinuation after initial use, limiting their overall adoption and market expansion.

Many popular contraceptive devices, particularly hormonal options like IUDs (intrauterine devices), implants, and vaginal rings, release hormones into the body. While these methods are highly effective in preventing pregnancy, they often come with a range of side effects that deter users from continued use. However, there are associated risks of infection and uterine perforation upon insertion, especially if not performed in a sterile environment or by trained healthcare professionals.

Some individuals are concerned about the long-term impact of hormonal contraceptive methods on their health, including fertility issues or increased cancer risk. There are fears that the use of hormonal devices like implants or IUDs may reduce fertility or delay the return to normal fertility after stopping use. However, these concerns are often based on misinformation or outdated studies.

Segment Analysis

The global contraceptive devices market is segmented based on product type, technology, gender, distribution channel, and region.

Product Type:

The condoms is expected to dominate in the product type segment of contraceptive devices market with the share.

The condoms segment holds a dominant position in the global contraceptive devices market due to several factors, including affordability, ease of use, dual protection against both pregnancy and sexually transmitted infections (STIs), and wide availability. The combination of these factors has made condoms the most widely used form of contraception worldwide.

One of the most significant reasons for the dominance of condoms is that they provide dual protection against both pregnancy and sexually transmitted infections (STIs). Unlike other contraceptive methods, such as IUDs or hormonal contraceptives, condoms are the only method that also helps prevent the transmission of diseases like HIV, chlamydia, and gonorrhea. This makes condoms particularly popular in regions with high rates of STIs.

For instance, according to the World Health Organization, 374 million new STI infections occurred globally among adults aged 15-49 with 1 of the 4 curable STIs: syphilis, chlamydia, gonorrhea, and trichomoniasis. Most of these could be prevented with the correct use of condoms.

Condoms are low-cost compared to other contraceptive methods, which makes them highly accessible to a wide demographic, including low-income populations. Many countries offer free or subsidized condoms through public health initiatives, making them available to even those in remote or underserved areas. The wide availability, coupled with affordability, has made condoms the most used method of contraception globally.

Geographical Analysis

North America is expected to hold a significant position in the contraceptive devices market with the highest market share

North America boasts one of the highest levels of awareness and education about family planning and sexual health globally. Comprehensive sex education programs, particularly in the U.S. and Canada, ensure that individuals have a clear understanding of contraception methods, their benefits, and their side effects. This has led to the widespread acceptance and use of various contraceptive devices.

For instance, according to the Guttmacher Institute, 99% of women aged 15-44 in the U.S. who have had sex have used at least one contraceptive method, with 75% of them using modern methods like IUDs, implants, and condoms. The high level of awareness about birth control options directly drives demand for contraceptive devices.

Governments in North America actively promote family planning and reproductive health through subsidies, awareness campaigns, and public health programs. These initiatives play a critical role in ensuring that contraceptive devices are accessible and affordable for a broad population. For instance, the United States government supports family planning through federal programs like Title X, which provides funding for family planning clinics.

Asia-Pacific is growing at the fastest pace in the contraceptive devices market

The Asia-Pacific region has the largest population in the world, with over 4.6 billion people, representing about 60% of the global population. This vast population, especially in countries like India and China, creates a substantial demand for family planning solutions and contraceptive methods. As the population continues to grow, governments and individuals are increasingly turning to contraception to control family sizes and improve reproductive health.

For instance, with a population exceeding 1.4 billion people, India is one of the world's most populous countries, and the demand for contraceptives is increasing as families seek to manage the birth rate. According to the National Family Health Survey (NFHS), over 50% of married women in India use modern contraceptive methods, with a significant portion opting for IUDs, condoms, and oral contraceptive pills. India's government has actively promoted family planning through programs like Mission Parivar Vikas, aiming to increase contraceptive prevalence.

Governments in the Asia-Pacific region play a critical role in promoting family planning and contraceptive use through policies and financial support. Many countries have established national programs to distribute contraceptive devices, reduce birth rates, and improve maternal health. This government backing has directly contributed to the growing contraceptive market. For instance, India has consistently emphasized family planning in its national policies, and its National Family Planning Program has expanded access to free or subsidized contraceptives across the country. This has led to a rise in the use of IUDs, oral contraceptives, and sterilization methods.

Competitive Landscape

The major global players in the contraceptive devices market include CooperSurgical, Inc., Pregna International Limited, Reckitt Benckiser Group, Veru Inc., Bayer AG, Abbvie Inc., EUROGINE, S.L., Mona Lisa N.V., Prosan International BV, and OCON Medical Ltd., among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global contraceptive devices market report delivers a detailed analysis with 70 key tables, more than 64 visually impactful figures, and 163 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Product Type
• 2.4. Snippet by Technology
• 2.5. Snippet by Gender
• 2.6. Snippet by Distribution Channel
• 2.7. Snippet by Region

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Increasing Awareness and Government Initiatives
    • 3.1.1.2. Rising Advancements in Contraceptive Devices
  • 3.1.2. Restraints
    • 3.1.2.1. Side Effects and Health Concerns
    • 3.1.2.2. High Cost of Contraceptive Devices
  • 3.1.3. Opportunity
    • 3.1.3.1. Government Initiatives
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with largest selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. CXO Perspectives
• 4.3. Latest Developments and Breakthroughs
• 4.4. Case Studies/Ongoing Research
• 4.5. Regulatory and Reimbursement Landscape
  • 4.5.1. North America
  • 4.5.2. Europe
  • 4.5.3. Asia Pacific
  • 4.5.4. Latin America
  • 4.5.5. Middle East & Africa
• 4.6. Porter's Five Forces Analysis
• 4.7. Supply Chain Analysis
• 4.8. Patent Analysis
• 4.9. SWOT Analysis
• 4.10. Unmet Needs and Gaps
• 4.11. Recommended Strategies for Market Entry and Expansion
• 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.13. Pricing Analysis and Price Dynamics
• 4.14. Key Opinion Leaders

5. Contraceptive Devices Market, By Product Type

• 5.1. Introduction
  • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 5.1.2. Market Attractiveness Index, By Product Type
• 5.2. Condoms*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 5.3. Diaphragms and Cervical Caps
• 5.4. Sponges
• 5.5. Vaginal Rings
• 5.6. Intrauterine Devices (IUDs)
• 5.7. Sub-dermal Implants

6. Contraceptive Devices Market, By Technology

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 6.1.2. Market Attractiveness Index, By Technology
• 6.2. Hormonal Contraceptives*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Barrier Contraceptives

7. Contraceptive Devices Market, By Gender

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
  • 7.1.2. Market Attractiveness Index, By Gender
• 7.2. Male*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Female

8. Contraceptive Devices Market, By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Hospital Pharmacies*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Retail Pharmacies
• 8.4. Online Channels
• 8.5. Others

9. Contraceptive Devices Market, By Regional Market Analysis and Growth Opportunities

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.7.1. U.S.
    • 9.2.7.2. Canada
    • 9.2.7.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.7.1. Germany
    • 9.3.7.2. U.K.
    • 9.3.7.3. France
    • 9.3.7.4. Spain
    • 9.3.7.5. Italy
    • 9.3.7.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.7.1. Brazil
    • 9.4.7.2. Argentina
    • 9.4.7.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.7.1. China
    • 9.5.7.2. India
    • 9.5.7.3. Japan
    • 9.5.7.4. South Korea
    • 9.5.7.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
  • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape and Market Positioning

• 10.1. Competitive Overview and Key Market Players
• 10.2. Market Share Analysis and Positioning Matrix
• 10.3. Strategic Partnerships, Mergers & Acquisitions
• 10.4. Key Developments in Product Portfolios and Innovations
• 10.5. Company Benchmarking

11. Company Profiles

• 11.1. CooperSurgical, Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
  • 11.1.5. SWOT Analysis
• 11.2. Pregna International Limited
• 11.3. Reckitt Benckiser group
• 11.4. Veru Inc.
• 11.5. Bayer AG
• 11.6. Abbvie Inc.
• 11.7. EUROGINE, S.L.
• 11.8. Mona Lisa N.V.
• 11.9. Prosan International BV
• 11.10. OCON Medical Ltd.

"*" Indicates similar breakdown for other companies

LIST NOT EXHAUSTIVE

12. Assumption and Research Methodology

• 12.1. Data Collection Methods
• 12.2. Data Triangulation
• 12.3. Forecasting Techniques
• 12.4. Data Verification and Validation

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us